Kian Kani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1328607/publications.pdf Version: 2024-02-01



KIANI KANU

#	Article	IF	CITATIONS
1	A cross-platform toolkit for mass spectrometry and proteomics. Nature Biotechnology, 2012, 30, 918-920.	17.5	2,794
2	Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13237-13242.	7.1	65
3	Anterior gradient 2 (AGR2): Bloodâ€based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate, 2013, 73, 306-315.	2.3	60
4	Oligomers of ERBB3 Have Two Distinct Interfaces That Differ in Their Sensitivity to Disruption by Heregulin. Journal of Biological Chemistry, 2005, 280, 8238-8247.	3.4	49
5	Precursor-Ion Mass Re-Estimation Improves Peptide Identification on Hybrid Instruments. Journal of Proteome Research, 2008, 7, 4031-4039.	3.7	49
6	Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells. Endocrine-Related Cancer, 2017, 24, 157-170.	3.1	27
7	The Extracellular Domains of ErbB3 Retain High Ligand Binding Affinity at Endosome pH and in the Locked Conformationâ€. Biochemistry, 2005, 44, 15842-15857.	2.5	24
8	Protein Mimetic and Anticancer Properties of Monocyte-Targeting Peptide Amphiphile Micelles. ACS Biomaterials Science and Engineering, 2017, 3, 3273-3282.	5.2	24
9	Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis. Oncogene, 2019, 38, 3003-3018.	5.9	23
10	CCR2-targeted micelles for anti-cancer peptide delivery and immune stimulation. Journal of Controlled Release, 2021, 329, 614-623.	9.9	22
11	The N-terminal Domains of Neuregulin 1 Confer Signal Attenuation. Journal of Biological Chemistry, 2006, 281, 27306-27316.	3.4	19
12	JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines. Molecular Cancer Therapeutics, 2017, 16, 1645-1657.	4.1	18
13	Impact of Protein Stability, Cellular Localization, and Abundance on Proteomic Detection of Tumor-Derived Proteins in Plasma. PLoS ONE, 2011, 6, e23090.	2.5	15
14	Quantitative Proteomics Using SILAC. Methods in Molecular Biology, 2017, 1550, 171-184.	0.9	12
15	Identification, characterization and application of a new peptide against anterior gradient homolog 2 (AGR2). Oncotarget, 2018, 9, 27363-27379.	1.8	9
16	Simulation of the Protein-Shedding Kinetics of a Fully Vascularized Tumor. Cancer Informatics, 2015, 14, CIN.S35374.	1.9	8
17	Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition. Molecular Cancer Therapeutics, 2012, 11, 1071-1081.	4.1	6
18	A blood biomarker for monitoring response to anti-EGFR therapy. Cancer Biomarkers, 2018, 22, 333-344.	1.7	3

Kian Kani

#	Article	IF	CITATIONS
19	Model-Based Discovery of Circulating Biomarkers. Methods in Molecular Biology, 2011, 728, 87-107.	0.9	2
20	Investigation of Acquired Resistance to EGFR-Targeted Therapies in Lung Cancer Using cDNA Microarrays. Methods in Molecular Biology, 2012, 795, 233-253.	0.9	1
21	Quantification of cancer cell migration with an integrated experimental-computational pipeline. F1000Research, 0, 7, 1296.	1.6	1
22	Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays. Journal of Visualized Experiments, 2018, , .	0.3	0
23	Abstract C58: Heterotetramers of ERBB2 and ERBB3 generate qualitatively distinct signals from heterodimers and provide most of the neuregulin-induced phosphorylation of ERBB2., 2011, , .		0